Background: There is a lack of comprehensive knowledge regarding the epidemiology of endocrine/metabolic disorders related to SARS-CoV-2 (COVID-19). Understanding the “cause and effects” of COVD-19 on endocrine / metabolic disorders can decrease the global morbidity and mortality and save billions of dollars in health care.

Hypothesis and Aim: Identification of the independent parameters based on age, sex, and illness to understand the effect of SARS-Cov2 on the different endocrine/metabolic disorders was carried out using the fixed and random-effects meta-analysis models as appropriate. Subsequently, PubMed, Scopus, and Google Scholar databases were searched up to January 2021, using suitable keywords.  Individual and pooled prevalence rates with 95% confidence intervals (CI) were calculated using the fixed or random effects model as appropriate.

Result: Based on our meta-analysis, COVID-19 shows high prevalence and incidence of common endocrine and metabolic disorders (hyperglycemia, hyperlipidemia, and altered thyroid as well as pituitary functions). Interestingly, hyperglycemic and hyperlipidemic conditions can trigger the release of proxidants/pro-inflammatory markers, induce hypoxia leading to organ failure. Furthermore, sex differences in the response to inflammation was observed in COVID-19 patients which may be due to sex steroid hormones. Age-associated decreases in estrogen and testosterone mediates proinflammatory mediators in older adults. On the other hand, hyperglycemic environment facilitates entry of COVID-19 by enhancing the surface expression of angiotensin converting enzyme2 (ACE2) through hyperinsulinemia-mediated reduction in protease activity (ADAMTS17). These endocrine/metabolic pathologies can cause obesity, increased risk of cardiovascular diseases which can decrease the lifespan drastically. Delineating the etiopathology of these conditions will provide clues to risk factors and identify areas to allocate public health and research resources.